TABLE 1.
Characteristics of the Patients Who Received Cladribine-based Therapy
| No. of patients (%) | |||
|---|---|---|---|
| Single-agent 2-CDA(NCCTG 95-80-53) |
2-CDA/Rituximab (NCCTG N0189) |
||
| Characteristic | Recurrent MCL (n = 24) |
Previously untreated MCL (n = 26) |
Previously untreated MCL (n = 29) |
| Median age [range], y | 68 [39–81] | 68 [42–81] | 70 [41–86] |
| Men | 20 (83) | 23 (89) | 21 (72) |
| Performance score | |||
| 0 | 12 (50) | 19 (73) | 16 (55) |
| 1 | 7 (29) | 6 (23) | 12 (41) |
| 2 | 5 (21) | 1 (4) | 1 (3.5) |
| Tumor stage | |||
| I/II | 6 (25) | 3 (12) | 3 (10) |
| III/IV | 18 (75) | 23 (88) | 26 (90) |
| Elevated LDH | 5 (21) | 8 (31) | 10 (34) |
| No. of extranodal sites | |||
| 0–1 | 12 (50) | 17 (65) | 11 (38) |
| ≥2 | 12 (50) | 9 (35) | 18 (62) |
| International Prognostic Factor Index | |||
| 0 | 2 (8) | 0 (0) | 0 (0) |
| 1 | 4 (17) | 8 (31) | 3 (10) |
| 2 | 9 (38) | 9 (35) | 10 (35) |
| 3 | 4 (17) | 7 (27) | 12 (41) |
| 4 | 4 (17) | 2 (8) | 4 (14) |
| 5 | 1 (4) | 0 (0) | 0 (0) |
2-CDA indicates cladribine; NCCTG, North Central Cancer Therapy Group; MCL, mantle cell lymphoma; LDH, lactate dehydrogenase.